Table 1 Baseline demographics and clinical characteristics of the study population in different cohort
From: Non-invasive diagnosis strategy of hepatocellular carcinoma in low-risk population
Characteristics | Train cohort (n = 324) | Internal validation cohort (n = 139) | External validation cohort (n = 218) | P value |
|---|---|---|---|---|
Age (y, median, IQR) | 59 (49, 66) | 60 (50, 67) | 53 (44, 68) | 0.001a |
Male (n, %) | 189 (58%) | 90 (65%) | 149 (68%) | 0.054 |
HCC (n, %) | 112 (35%) | 62 (45%) | 103 (48%) | 0.006 |
Family history (n, %) | 11 (3%) | 3 (2%) | 20 (9%) | 0.004 |
Cigarette (n, %) | 69 (21%) | 33 (24%) | 57 (26%) | 0.012 |
Alcohol (n, %) | 42 (13%) | 31 (22%) | 57 (26%) | < 0.001 |
Cardiovascular disease (n, %) | 67 (21%) | 44 (32%) | 33 (15%) | 0.001 |
Diabetes (n, %) | 39 (12%) | 21 (15%) | 27 (12%) | 0.683 |
HCV (n, %) | 3 (1%) | 7 (1%) | 2 (1%) | 1.000 |
HBeAb + (n, %) | 104 (32%) | 58 (42%) | 94 (43%) | 0.018 |
HBcAb + (n, %) | 216 (67%) | 58 (42%) | 94 (43%) | 0.039 |
Platelet (median, IQR) | 238 (184, 304) | 227 (181, 293) | 237 (194, 285) | 0.629a |
ALT (median, IQR) | 25 (17, 49) | 23 (15, 39) | 24 (16, 35) | 0.062a |
AST (median, IQR) | 30 (21, 51) | 27 (20, 44) | 22 (18, 30) | < 0.001a |
GGT (median, IQR) | 86 (46, 203) | 76 (36, 175) | 46 (28, 82) | < 0.001a |
ALP (median, IQR) | 107 (77, 186) | 92 (72, 142) | 85 (66, 111) | < 0.001a |
AFP > 20 ng/L (n, %) | 68 (21%) | 32 (23%) | 57 (26%) | 0.374 |
CEA > 5ug/L (n, %) | 62 (19%) | 25 (18%) | 23 (11%) | 0.020 |
CA125 > 35U/ml (n, %) | 81 (25%) | 31 (22%) | 3 (1%) | < 0.001 |
CA19-9 > 129U/ml(n, %) | 66 (20%) | 32 (23%) | 13 (6%) | < 0.001 |
Size > 3 cm (n, %) | 259 (80%) | 116 (83.5%) | 117 (81.2%) | 0.697 |